Third Quarter 2023 Earnings

revvity

October 30, 2023

Safe Harbor

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the “Financial Information” section of our website at www.revvity.com.

Key Takeaways

Innovation	Transformation	Performance
Introduced first line of "Pin-Point" base editing reagents. Quantum GX3 and IVIS Spectrum 2 in vivo imaging instruments launched	Executing on key operational & commercial initiatives during first full quarter as Revvity	Strong expense management and capital deployment helped offset challenging end market demand environment

A Scientific Solutions Company Helping To Solve The World's Greatest Health Challenges From Discovery To Development, and Diagnosis to Cure

3Q23 Revenue Highlights

Segments



Geographic



Product Mix



revvity

Revenue performance provided on a non-COVID organic basis

Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

3Q23 Financial Results

ADJUSTED REVENUE	ADJUSTED OP MARGIN	ADJUSTED EPS	NON-GAAP FREE CASH FLOW
$671M	27.5%	$1.18	$8M
⬇ -6% y/y	⬇ -390bps y/y	⬇ -3% y/y	⬇ -131% y/y
Organic: -7% | M&A: 0% | FX: 1%	Adj. Gross Margin: 61.0% | -300bps y/y	Adj. Tax Rate: 17.8%	Includes $21M of AES related outflows
Non-COVID: +1% organic growth		Adj. Net Interest & Other: $7M	
COVID: De minimis vs. $54M in 3Q'22			

Life Sciences

Product



REVENUE	AJUSTED OP MARGINS
-3% Organic Growth	37.1%
Reported: -2% | M&A: 0% | FX: 1%	-30bps y/y

- -HSD decline from Pharma/Biotech, +LDD growth from Academic/Gov't
- Reagent growth pressured by year ago licensing and softening reagent demand vs. 2Q
- Software growth due to contract renewal timing

Diagnostics

End Market



REVENUE	AJUSTED OP MARGINS
-10% Organic Growth	22.5%
Reported: -9% | M&A: 0% | FX: 1%	-840 bps y/y
Non-COVID Organic Growth: 4%	

- +High-teens ImmunoDX globally, including in China
- +MSD Newborn performance offset by Revvity Omics contract timing
- -LDD Non-COVID organic growth in Applied Genomics across instruments and consumables

Revenue and revenue performance provided on a non-COVID organic basis

Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

2023 Financial Guidance

ADJ. REVENUE	**$2.72B - 2.74B**
	-18% to -17% reported
	Organic: -17%
	Non-COVID Organic: 2%
	FX: -1%, M&A: 0%
ADJUSTED OP. MARGIN	**~28%**
ADJUSTED EPS	**$4.53 - $4.57**
	Adj. Net interest expense, other: $57M
	Adjusted tax rate: ~20%
	Average diluted share count: 125M



Revvity.com